• Home
  • Agenda
  • Speakers
  • Partners
    • Commercial Partners
    • Media Partners
    • Become a Commercial Partner
    • Host a webinar
  • Summit Details
    • Venue & Accommodation
    • FAQS
    • Sign up for conference updates
    • Contact Us
  • Attendance
    • Why attend
    • Gallery
    • Audience Breakdown
    • Poster Competition
    • Ticket details
  • DDF Summits
    • DDF Global
    • DDF Asia
  • LOG IN
  • Book now
Zerion
www.zerion.eu

Zerion Pharma A/S is a pharmaceutical company aspiring to transform the pharmaceutical landscape for the formulation of poorly soluble drugs that are currently not reaching their therapeutic potential.

The company was established in 2019 as a spinout from the University of Copenhagen based on a decade of research. Zerion Pharma has pioneered the Dispersome® technology that greatly enhances the solubility of poorly soluble, oral drugs and improves bioavailability and therapeutic options for patients.

The Dispersome® technology is based around a class of novel excipient, namely beta-lactoglobulin (BLG), to formulate poorly soluble small molecule drugs into stable amorphous drug delivery systems with a high drug load. By increasing solubility and dissolution rate, the Dispersome® platform aims at improving bioavailability and therapeutic outcomes and reducing adverse effects in patients. The Dispersome® technology is well accepted with no safety risks and is compatible with standard solid oral dosage form manufacturing.

Back

Information


Mark Allen Group
St Jude’s Church
Dulwich Road
London
SE24 0PB
United Kingdom

Main reception at Publication company: +44 (0)20 7738 5454


Additional Enquiries:


Alexandra Krcho, Account Director +44 (0)20 3874 9205
Adrian Forde, Delegate Sales Director + 44 (0)20 3874 9209

[Privacy Policy] – Please read our privacy policy to understand how we process, use, and safeguard your data.

Further information


Privacy policy

Cookie policy

Terms and conditions

Booking terms and conditions